Drug intelligence / Profile preview

REVIVE

Development stage: Unknown
Lead developer: RegenMed
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Injection

Overview

REVIVE is an exosome-based regenerative therapy developed by RegenMed Asia. It utilizes extracellular vesicles (EVs) to facilitate paracrine signaling between cells, delivering bioactive molecules such as proteins, lipids, and nucleic acids to target tissues. This mechanism is intended to stimulate cellular repair, modulate inflammatory responses, and promote rejuvenation. The product is primarily indicated for anti-aging and general tissue repair, and it is currently marketed as a commercially available regenerative treatment.

Brand names: REVIVE
Other names: Extracellular VesiclesExosomes

Beyond the preview

Go deeper on REVIVE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REVIVE.

Explore the full profile